A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
Public ClinicalTrials.gov record NCT05730036. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-label, Randomized, Phase 3 Study of Linvoseltamab (REGN5458; Anti- BCMA x Anti-CD3 Bispecific Antibody) Versus the Combination of Elotuzumab, Pomalidomide, and Dexamethasone (EPd), in Patients With Relapsed/Refractory Multiple Myeloma (LINKER-MM3)
Study identification
- NCT ID
- NCT05730036
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Enrollment
- 410 participants
Conditions and interventions
Conditions
Interventions
- Dexamethasone Drug
- Elotuzumab Drug
- Linvoseltamab Drug
- Pomalidomide Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 17, 2023
- Primary completion
- Apr 18, 2033
- Completion
- Apr 18, 2033
- Last update posted
- Mar 5, 2026
2023 – 2033
United States locations
- U.S. sites
- 10
- U.S. states
- 8
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California Los Angeles (UCLA) | Los Angeles | California | 90095 | Active, not recruiting |
| University of Florida Division of Sponsored Programs | Gainesville | Florida | 32611 | Withdrawn |
| University of Kentucky, Markey Cancer Center Clinical Research Organization | Lexington | Kentucky | 40536 | Active, not recruiting |
| Norton Cancer Institute | Louisville | Kentucky | 40207 | Active, not recruiting |
| Stony Brook University | Stony Brook | New York | 11794 | Active, not recruiting |
| Levine Cancer Center | Charlotte | North Carolina | 28204 | Active, not recruiting |
| Duke University Medical Center | Durham | North Carolina | 27705 | Withdrawn |
| Kaiser Permanente Northwest | Portland | Oregon | 97227 | Active, not recruiting |
| MD Anderson Cancer Center | Houston | Texas | 77030 | Active, not recruiting |
| University of Washington | Seattle | Washington | 98195 | Active, not recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 149 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05730036, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 5, 2026 · Synced May 9, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05730036 live on ClinicalTrials.gov.